NR2F6 and neoplasm: As a remarkable result, 66.67% or 8 out of 12 mice receiving CD3CRISPR.Nr2f6 with αCTLA-4 (Fig. 4h, i) and 37.5% (3/8) with αPD-L1 (Fig. 4d, e) therapy survived the tumor burden.